- Companies
- InSilico Medicine Cayman
InSilico Medicine Cayman Valuation Multiples
InSilico Medicine Cayman is valued at $2.7B as of October 2026, a 37.2x revenue multiple. In the last fiscal year, InSilico Medicine Cayman revenue was $56M and InSilico Medicine Cayman EBITDA was ($353M).
InSilico Medicine Cayman Overview
About InSilico Medicine Cayman
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
Founded
2018
HQ
Employees
333
Website
Sectors
Financials (Last FY)
EV
$2.1B
Valuation Multiples
Start free trialInSilico Medicine Cayman Financials
InSilico Medicine Cayman reported last fiscal year revenue of $56M and negative EBITDA of ($353M).
In the same fiscal year, InSilico Medicine Cayman generated $46M in gross profit, ($353M) in EBITDA losses, and had net loss of ($352M).
InSilico Medicine Cayman P&L
In the most recent fiscal year, InSilico Medicine Cayman reported revenue of $56M and EBITDA of ($353M).
InSilico Medicine Cayman is unprofitable as of last fiscal year, with gross margin of 82%, EBITDA margin of (627%), and net margin of (626%).
Financial data powered by Morningstar, Inc.
InSilico Medicine Cayman Stock Performance
InSilico Medicine Cayman has current market cap of $2.7B, and enterprise value of $2.1B.
Market Cap Evolution
InSilico Medicine Cayman's stock price is $4.59.
InSilico Medicine Cayman share price decreased by 40.1% in the last 30 days.
InSilico Medicine Cayman has an EPS (earnings per share) of $-0.61.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $2.7B | -6.7% | -40.1% | -21.2% | - | $-0.61 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInSilico Medicine Cayman Valuation Multiples
InSilico Medicine Cayman trades at 37.2x EV/Revenue multiple, and (5.9x) EV/EBITDA.
InSilico Medicine Cayman Financial Valuation Multiples
As of October 23, 2026, InSilico Medicine Cayman has market cap of $2.7B and EV of $2.1B.
InSilico Medicine Cayman has a P/E ratio of (7.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified InSilico Medicine Cayman Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


InSilico Medicine Cayman Margins & Growth Rates
In the most recent fiscal year, InSilico Medicine Cayman reported gross margin of 82%, EBITDA margin of (627%), and net margin of (626%).
InSilico Medicine Cayman Margins
InSilico Medicine Cayman Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
InSilico Medicine Cayman Operational KPIs
InSilico Medicine Cayman's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
InSilico Medicine Cayman Competitors
InSilico Medicine Cayman competitors include Intsig Information, Hebei Changshan, Yili Chuannig Biotech, BioArctic, Kangmei Pharmaceutical Co., Viridian Therapeutics, AtaiBeckley, Kanghong Pharmaceutical, NewAmsterdam Pharma and Betta Pharmaceuticals.
Most InSilico Medicine Cayman public comparables operate across Biopharmaceuticals, Artificial Intelligence, Vertical AI Applications, Life Sciences Tools, Generative AI, BioTech and HealthTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $271M | $84M | 7.9x | 6.5x | 25.6x | 23.6x | |||
| $131M | ($29M) | 23.0x | - | (105.5x) | - | |||
| $692M | $233M | 3.8x | 4.0x | 11.3x | 12.2x | |||
| $202M | $125M | 12.4x | 16.6x | 20.1x | 38.0x | |||
| $787M | $54M | 3.1x | - | 44.6x | - | |||
| $71M | ($365M) | 27.5x | 58.7x | (5.3x) | (4.7x) | |||
| $4M | ($659M) | 611.9x | 740.8x | (3.8x) | (12.2x) | |||
| $687M | $231M | 2.6x | 2.6x | 7.7x | 7.9x | |||
This data is available for Pro users. Sign up to see all InSilico Medicine Cayman competitors and their valuation data. Start Free Trial | ||||||||
InSilico Medicine Cayman VC Funding History
Before going public, InSilico Medicine Cayman raised $647M in total equity funding, across 11 rounds.
Last private valuation of InSilico Medicine Cayman was $1B, after raising $123M in March 2025 from Shanghai Pudong, Wuxi Capital, Dahong Touzi, and 8 other investors.
InSilico Medicine Cayman Funding Rounds
Investments by InSilico Medicine Cayman
InSilico Medicine Cayman has invested in 1 company to date.
Latest investment by InSilico Medicine Cayman was on July 21st 2026. InSilico Medicine Cayman invested in Yuanma Intelligent Pharmaceuticals in their Seed round.
Latest Investments by InSilico Medicine Cayman
| Description | Yuanma Intelligent Pharmaceuticals is a Shanghai-based biopharmaceutical company developing circular mRNA technologies for in vivo CAR-T cell therapies targeting solid tumors and hematologic malignancies. Operating via its Byterna platform, it advances cmRNA delivery systems to improve efficacy over traditional mRNA, with preclinical data presented at international oncology conferences. |
| HQ Country | |
| HQ City | Shanghai |
| Deal Date | 21 Jul 2026 |
| Round | Seed |
| Raised | undisclosed |
| Investors | InSilico Medicine Cayman; EFung Capital |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all InSilico Medicine Cayman investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout InSilico Medicine Cayman
| When was InSilico Medicine Cayman founded? | InSilico Medicine Cayman was founded in 2018. |
| Where is InSilico Medicine Cayman headquartered? | InSilico Medicine Cayman is headquartered in United States. |
| How many employees does InSilico Medicine Cayman have? | As of today, InSilico Medicine Cayman has over 333 employees. |
| Who is the CEO of InSilico Medicine Cayman? | InSilico Medicine Cayman's CEO is Alex Zhavoronkov. |
| Is InSilico Medicine Cayman publicly listed? | Yes, InSilico Medicine Cayman is a public company listed on HKEX. |
| What is the stock symbol of InSilico Medicine Cayman? | InSilico Medicine Cayman trades under 03696 ticker. |
| When did InSilico Medicine Cayman go public? | InSilico Medicine Cayman went public in 2025. |
| Who are competitors of InSilico Medicine Cayman? | InSilico Medicine Cayman main competitors include Intsig Information, Hebei Changshan, Yili Chuannig Biotech, BioArctic, Kangmei Pharmaceutical Co., Viridian Therapeutics, AtaiBeckley, Kanghong Pharmaceutical, NewAmsterdam Pharma, Betta Pharmaceuticals. |
| What is the current market cap of InSilico Medicine Cayman? | InSilico Medicine Cayman's current market cap is $2.7B. |
| What is the current revenue of InSilico Medicine Cayman? | InSilico Medicine Cayman's last fiscal year revenue is $56M. |
| What is the current EV/Revenue multiple of InSilico Medicine Cayman? | Current revenue multiple of InSilico Medicine Cayman is 37.2x. |
| Is InSilico Medicine Cayman profitable? | No, InSilico Medicine Cayman is not profitable. |
| How many companies InSilico Medicine Cayman has acquired to date? | InSilico Medicine Cayman hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies InSilico Medicine Cayman has invested to date? | As of October 2026, InSilico Medicine Cayman has invested in 1 company. |
| What was the last InSilico Medicine Cayman investment? | On 21st July 2026 InSilico Medicine Cayman invested in Yuanma Intelligent Pharmaceuticals, participating in a Seed round, alongside EFung Capital. |
| In what companies InSilico Medicine Cayman invested in? | InSilico Medicine Cayman invested in Yuanma Intelligent Pharmaceuticals. |
See public comps similar to InSilico Medicine Cayman
Lists including InSilico Medicine Cayman
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




